$$
1 ( \infty + 0 . 2 0 7 - 1
$$

# 5. 510(k) Summary

# Owner's Name & Address:

Diamond Diagnostics Inc 333 Fiske Street Holliston MA 01746 FAX: 508-429-0452

# OEC - 1 2006

Establishment Registration Number: 3003030793

# Date of Preparation: Identification of the Device:

September 1, 2006

Proprietary/Trade name: Common name Classification name:

Mission Trinity B blood gas controls with electrolytes, glucose and dyes controls for blood-gases (assayed and un-assayed) (Classification # 862.1660, Product Code JJY)

Substantial Equivalence Table of Product Part Numbers & Trade Names   

<table><tr><td rowspan=1 colspan=1>Diamond/Mission Product</td><td rowspan=1 colspan=1>Bayer Equivalent</td></tr><tr><td rowspan=1 colspan=1>DD-96001 Trinity B Level 1</td><td rowspan=1 colspan=1>108860Rapid Complete Level 1</td></tr><tr><td rowspan=1 colspan=1>DD-96002 Trinity B Level 2</td><td rowspan=1 colspan=1>108868Rapid Complete Level 2</td></tr><tr><td rowspan=1 colspan=1>DD-96003 Trinity B Level 3</td><td rowspan=1 colspan=1>108869 RapidComplete Level 3</td></tr><tr><td rowspan=1 colspan=1>DD-96123Trinity B Levels 1,2,3</td><td rowspan=1 colspan=1>Not available</td></tr></table>

# Description of New Device:

the Bayer ne f blood gas,electrolyte,metabolite and CO-Oximety analyzers.Trinity Bcontros proie a quality assurance program.

t cally eet qtt  s shc gcastablecratinulanicelevantvaluego hemoglobin derivatives: O2Hb, COHb, MetHb and HHB.

# Intended Use:

nuala fmghe peorn bloo gas elecrolyetaboliand O-Oxi (Baye 7/80/40 s instrumentation for the analytes listed on the Expected Values Chart.

Comparison of Technological Characteristics with Predicate Device:   

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>Mission Trinity B</td><td rowspan=1 colspan=1>Bayer Rapid Complete</td></tr><tr><td rowspan=1 colspan=1>PN</td><td rowspan=1 colspan=1>DD-96001, 96002, 96003, 96123</td><td rowspan=1 colspan=1>108860, 108868, 108869</td></tr><tr><td rowspan=1 colspan=1>Contents:Any Level</td><td rowspan=1 colspan=1>Aqueous solution of buffers, electrolytes, glucose,lactate, dyes, equilibrated with CO2, O2 and N2.Contains NO human or animal materials.</td><td rowspan=1 colspan=1>Aqueous solution of buffers, electrolytes, glucose,lactate, dyes, equilibrated with CO2, O2 and N2.Contains NO human or animal materials.</td></tr><tr><td rowspan=1 colspan=1>Container</td><td rowspan=1 colspan=1>Glass ampule (heat sealed, score break)</td><td rowspan=1 colspan=1>Glass ampule (heat sealed, score break)</td></tr><tr><td rowspan=1 colspan=1>Color</td><td rowspan=1 colspan=1>Red/purple solution</td><td rowspan=1 colspan=1>Red/purple solution</td></tr><tr><td rowspan=1 colspan=1>Package</td><td rowspan=1 colspan=1>30 X 1.8mL (instrument only requires a fraction aof an mL to make a measurement)</td><td rowspan=1 colspan=1>30 X 2.5mL</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For in-vitro diagnostics use for quality control ofpH/Blood Gas analyzers, ISE analyzers, CO-oximeters, and Metabolite analyzers.</td><td rowspan=1 colspan=1>For in-vitro diagnostics use for quality control ofpH/Blood Gas analyzers, ISE analyzers, CO-oximeters, and Metabolite analyzers.</td></tr><tr><td rowspan=1 colspan=1>&#x27;torage / ShelfLife</td><td rowspan=1 colspan=1>2-8째C (36-months) or 18-25째C 12-months</td><td rowspan=1 colspan=1>2-8째C or 18-25째C (until expiration date)</td></tr></table>

# Assessment of Non-Clinical Performance Data:

ere conducted to verify specific performance requirements:   
Accelerated (high temperature) stress test to support stability Side by side testing of Mission Trinity B vs. Predicate (OEM) product on intended instruments to demonstrate equivalence

# Assessment of Clinical Performance Data:

NA

# Conclusions:

Cglav support the claim of substantial equivalence.

Randolph Quinn   
Development & Compliance Manager Diamond Diagnostics Inc.   
333 Fiske Street   
Holliston, MA 01746

DEC - 1 2006

Re: k062674 Trade/Device Name: Mission Trinity B Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJY Dated: September 1, 2006 Received: September 8, 2006

Dear Mr. Quinn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/1c201f58c3dc8a6fb5781e55f2372b57673216346f9baaf27a20d7d8f3f463de.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Page 3 -

cc: HFZ-401 DMC HFZ-404 510(k) Staff HFZ- Division D.O.

# 4Indications for Use Statement

510(k) Number (if known):

![](images/0ec38c8558235ef4708170266cd56bf79d392d52f860a45e0252f7d20dbd2edd.jpg)

Device Name: Mission Trinity B

Indications For Use:

pCO2, pO2, $\mathsf { N a } +$ $\mathsf { K } +$ $\mathtt { C a + + }$ , Cl-, glucose, lactate, tHb, %O2Hb, %COHb, %metHb & %HHb on Bayer instrumentation.

vision Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety K062674